Merck & Co. (MRK)
(Delayed Data from NYSE)
$113.09 USD
-1.64 (-1.43%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $113.01 -0.08 (-0.07%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.09 USD
-1.64 (-1.43%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $113.01 -0.08 (-0.07%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
Zacks News
The Zacks Analyst Blog Highlights: Merck, Tractor Supply, IDEXX and CVS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Tractor Supply, IDEXX and CVS
Lilly's Study on Higher Doses of Trulicity Meets Endpoint
by Zacks Equity Research
Lilly's (LLY) phase III study evaluating higher doses of Trulicity meets primary and secondary efficacy endpoints.
FDA Accepts Sanofi's BLA for Meningitis Vaccine to Review
by Zacks Equity Research
The FDA accepts for review Sanofi's (SNY) BLA for MenQuadfi, a meningococcal vaccine candidate, presently under development to prevent meningococcal meningitis.
Bayer Sets Up Special Committee to Tackle Glyphosate Lawsuits
by Zacks Equity Research
Activist investor, Elliott Advisors, discloses a 1.1-billion-euro ($1.3 billion) stake in Bayer (BAYRY). It forms a new committee and hires U.S. lawyer Beisner to fight its glyphosate litigations.
Is Allergan a Good Deal for AbbVie?
by Sejuti Banerjea
AbbVie is dishing out $63 billion in stock and cash for Allergan, provided it gets regulatory approval.
4 Stocks to Make the Most of the Growing Love for Pets
by Tirthankar Chakraborty
With the U.S. pet industry poised to grow 3.9% to a record $75.4 billion this year, here are few stocks that could gain from the growing love for animals.
Merck (MRK) Stock Moves -0.33%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $85.23, moving -0.33% from the previous trading session.
Bristol-Myers to Sell Otezla for Celgene Merger, Shares Down
by Zacks Equity Research
Bristol-Myers (BMY) declines as it announces to sell Otezla to settle FTC concerns, while Opdivo fails in liver cancer study.
The Zacks Analyst Blog Highlights: Microsoft, Chevron, Cisco, Merck and Visa
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Chevron, Cisco, Merck and Visa
Why These Innovative Biotech ETFs Are Soaring
by Neena Mishra
Strong M&A activity has sent shares of many small, innovative biotech companies surging
Will Pharmacy International Hit Walgreens (WBA) Q3 Earnings?
by Zacks Equity Research
Challenging market conditions, especially in retail, causes a slowdown in the Retail Pharmacy International division at Walgreens Boots (WBA).
Verastem Up on Positive Data From Early-Stage Copiktra Study
by Zacks Equity Research
Verastem (VSTM) presents encouraging data from an early-stage study evaluating its recently approved drug, Copiktra, for treating peripheral T-cell lymphoma.
Dow on Pace for Best June: 5 Blue Chip Stocks to Buy
by Tirthankar Chakraborty
Dow eyes best June in 80 years as investors cheer the Fed's shift to a more dovish stance.
Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval
by Zacks Equity Research
Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.
Sanofi/Regeneron's Asthma Candidate Meets Goal in Study
by Zacks Equity Research
Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.
Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma
by Swarup Gupta
The index enjoyed another week of strong gains after the Federal Reserve indicated that a rate cut would likely occur next month.
Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod
by Kinjel Shah
Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.
Are You Looking for a Top Momentum Pick? Why Merck (MRK) is a Great Choice
by Zacks Equity Research
Does Merck (MRK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Stock Market News For Jun 20, 2019
by Zacks Equity Research
Wall Street closed higher on Wednesday after the Fed kept the federal fund target rate unchanged.
AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod
by Zacks Equity Research
AstraZeneca (AZN) gets approval in Japan for PT010, its triple-combo inhaler and Bevespi Aerosphere, a fixed-dose LABA/LAMA inhaler, both to treat COPD.
Merck's Keytruda Gets 2nd Label Expansion Approval in June
by Zacks Equity Research
Merck (MRK) receives FDA approval for Keytruda's label expansion in small cell lung cancer indication, marking the drug's first approval in this indication.
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $84.45 in the latest trading session, marking a +1.38% move from the prior day.
Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients
by Zacks Equity Research
Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.
AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use
by Zacks Equity Research
AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.